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Abstract 
Fourier transform infrared spectroscopy (FTIR) has been shown to be a promising tool for identifying 
the mode of action of drugs. However, most previous studies have focused on the analysis of fixed 
or dried cells. The measurement of living cells has the advantage of obtaining time series data and 
the in-situ approach eliminates the need for fixing or drying the cells. In this study, the potential of 
live-cell FTIR method for the identification of the mode of action of drugs was demonstrated. Four 
different drugs were tested, with two of the drugs having the same mode of action (tamoxifen and 
toremifene), and the other two having different modes of action (imatinib and doxorubicin). Live 
cells were treated in the four drugs at and below the IC50 level (i.e. the concentration of drug 
required to inhibit the growth of cells by 50%), and the changes to their spectra after the addition of 
drugs were monitored over a 24-hour period. Principal component analysis (PCA) of the spectral 
data shows that drugs with different modes of action are well-separated, while the drugs with same 
mode of action are grouped together. The results also show that at IC50, the separation appears to 
be the clearest at 2 hours for imatinib, tamoxifen/toremifene and 6 hours for doxorubicin. However, 
at 50% IC50 drug concentration, the separation appears to be the best at longer incubation time, i.e. 
24 hours, for all four drugs. In conclusion, live-cell FTIR has shown to be able to distinguish and 
group spectral signatures of cells treated with drugs of known modes of action after a relatively 
short time of exposure. Further collection of live-cell data would enable an algorithm to be 
developed for the prediction of the modes of action of novel drugs, which can help in the preclinical 
drug screening process.  
  
Introduction 
The drug discovery process involves a high-throughput screening assays which use either in vitro 
cell-free bioassays or an in-silico approach, followed by in vitro validation. However, cell-free assays 
and in silico approaches lack mechanistic information and cellular penetration considerations, 
resulting in a high attrition of compounds and high cost. Current biochemical in vitro cell assays that 
are used in anticancer developments rely on destructive techniques that are expensive, time 
consuming and laborious.1, 2 Fourier transform infrared (FTIR) spectroscopy is a chemically specific, 
label-free and non-destructive analytical method for biological samples.3 The application of FTIR 
spectroscopy for drug-cells interaction analysis has attracted much attention,4, 5  with number of 
studies focusing on dry or fixed cells.5-10 The method has shown great promises in characterising the 
mode of action of drugs based on the changes to the chemical composition of the drug-treated cells 
at specific time point.11 However, the development in the FTIR measurement of live cells has allowed 
measurement of living cells at different time points during treatment.12-20 Another advantage of this 
in situ approach is that drying or fixing of cells is not carried out, reducing the chance of introducing 
experimental artefacts. Chemical changes such as cellular metabolites, proteins and nucleic acids 
inside the living cells can be followed in real time after the addition of drugs, maximising the 
potential of this technique for the understanding of the mechanism of drugs action.  
Measurement of living cells has been a challenging task because cells are generally cultivated in 
culture medium, i.e. surrounded by water, and the most common medium requires a humid 
atmosphere with 5% CO2 supplement for the buffer to maintain a physiological pH. We have shown 
that plain phosphate-buffered saline solution cannot maintain the viability of cells for more than a 
few hours, with rapid changes to the cellular composition observed.21 Effectively, mini-CO2 
incubators were built in the early live cell spectroscopic studies, or a specific flow cell was required 
to maintain the viability of the cells during measurement.22 Furthermore, water has strong 
absorbance in the mid-IR region, which often requires the path length of the IR light in the sample to 
be controlled and small (<10 µm). Spectral regions where water has strong absorption (~1650-1620 
cm-1) often results in a poor signal to noise ratio (SNR) that severely reduces the applicability of this 
method in the study of living cells. Raman spectroscopy has the advantage of low water absorption 
and shown interesting applications for the study of cellular changes in the Raman spectra after drug 
application and intracellular probing of drugs and its metabolites. However, the main drawback of 
conventional Raman spectroscopy is the longer acquisition time which limits its use in drug screening 
approach.23-26  
Infrared synchrotrons with brightness of several orders of magnitude higher than an ordinary Globar 
source have been used to partially overcome this problem. Using synchrotron sources, the 
measurement of infrared spectra of living cells within a reasonable time frame has been successfully 
demonstrated,27, 28 including the characterisation of normal cells from carcinoma,29 response of cells 
to mechanical stress,30 apoptotic pathways,31 chemical stress,12 optical stimulation,32 protein 
aggregation,17, 33 drug actions,10 toxicity in living algae34 and imaging with subcellular spatial 
resolution using ZnS hemispheres.35 However, access to synchrotron facilities are limited and 
therefore measurements of living cells that can be carried out in an ordinary laboratory remains 
highly desirable. The use of bench-top (non-synchrotron) FTIR imaging to measure a population of 
living cells in transmission mode has shown that the SNR can be improved by using principle 
component reconstruction, allowing the distinguishing of cells before and after the treatment of 
drugs.36, 37 Other recent demonstrations of non-synchrotron based single living cells transmission 
imaging include the use of a pair of CaF2 hemispheres to increase magnification and remove 
spherical and chromatic aberrations in a microfluidic device. A set of spectra of live cells with high 
SNR were obtained, with spectral changes identified before and after cell attachment.14  
Apart from transmission FTIR, the study of living cells utilising attenuated total reflection (ATR) 
sampling methods was shown to be suitable for live cells studies.38 ATR FTIR imaging has been 
previously employed to study the dissolution of pharmaceutical substances in order to avoid over-
absorbance due to the presence of water.39 Furthermore, the sampling volume of the ATR method is 
restricted by the depth of penetration, which is typically ~2 µm above the surface of the ATR 
element where cells are attached. The infrared absorbance signal is mostly contributed from the 
attached cell because the depth of penetration of the IR light is typically smaller than the thickness 
of an attached cell, which is on the order of 4-5 µm.40  Several earlier works have demonstrated that 
the ATR FTIR method is suitable for live cells studies.22, 41-49  We have demonstrated the use of the 
CO2 independent L15 medium to simplify the measurement and shown that drug concentration as 
little as 15 M can be detected in live cells.15, 16   
While most of the live cell-drug interaction studies were focused on the differences before and after 
the treatment of the drug, there been no direct comparison using live cells measurements of the 
effect of different drugs with different modes of action. In this preliminary work, we are 
demonstrating for the first time that live-cell FTIR using the multi-bounce ATR approach combined 
with principal component analysis (PCA), can be a powerful technique to separate drugs with 
different modes of action while grouping drugs with the same modes of action. The overall aim is to 
develop this method as a complementary tool in the drug screening process.  
The interest of this study is breast cancer cells and MDA-MB-231 is among breast cancer cells that 
are used in the National Cancer Institute 60 (NCI60) screening approach.2, 50 It is an invasive, hard to 
treat cancer and attract a lot of interest for finding new anticancer drugs. We will use this cell line in 
the demonstration of live cells study using multi-bounce ATR FTIR approach. 
Experimental Section 
 
Multi-bounce ATR-FTIR accessory 
A temperature controlled 10-reflection (10 internal reflections on the sample side) ATR accessory 
trough plate (HATR, Pike technologies) and 45° ZnS ATR element (80 mm X 10 mm X 4 mm, Crystan 
Ltd., UK) were used. The effective path length obtained in the living cells produced from this 
accessory is approximately 20-30 µm, with a depth of penetration (dp) nearly 2-3 µm. The trough 
plate has a measurement surface of about 500 mm2, where live cells adhere and continuously 
measured. 
 
Figure 1: Schematic of the multi-reflection ATR-FTIR measurement setup 
Live cell preparation 
MDA-MB-231 cells (obtained from the maintained stock (passage number 4) of cell lines from Dr 
Khondaker Miraz Rahman, Institute of Pharmaceutical Science, King’s College London) were 
maintained in T25 cell culture flasks using DMEM high glucose medium with 10% FBS, 1% MEM 
NEAA, 2 mM L-glutamine, 100 U/mL penicillin and 100 U/mL streptomycin and incubated in a 5% 
CO2 and 37°C incubator. The cells were trypsinised and harvested when they reached ~90% 
confluence and then centrifuged into a pellet. The pellet was then re-suspended in L15 medium, 
supplemented with 10% FBS, 1% MEM NEAA, 2 mM L-glutamine, 100 U/mL penicillin and 100 µg/mL 
streptomycin, to reach a cell density of ~ 0.5 x 106 cells/mL and total of 2.0 mL of suspension (i.e ~ 
1.0 X 106 cells). The cell suspension was directly seeded onto the multi-bounce trough plate 
controlled at 37 °C and sealed with a heated glass cover lid at 37 °C, to control the temperature in 
the measurement chamber. After 24 hours of incubation, the high seeding density ensured that cells 
are attached to the measurement surface as a monolayer with high (~90%) confluence. A reflective 
optical microscope with a 10x objective (L2003 microscope fitted with a digital camera) was used to 
confirm the confluence and attachment of cells to the measurement surface (see supplementary 
Figure 1S). 
Determination of cell viability 
Cell viability was determined using standard MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide) tetrazolium reduction assay.51 In brief, MDA-MB-231 Cells (2 x 104 
cells/well) were seeded in a 96-well plate and allowed to grow in the L15 medium for 24 hours at 
37°C, until a comparable confluence (~90%) to the ATR-FTIR experiment was observed in the wells. 
The medium was then replaced by the L15 medium, which contains different concentrations of 
tamoxifen, toremifene, imatinib (dissolved in DMSO) and doxorubicin (dissolved in water) and was 
then incubated for another 24 hours. In all treatments, the final concentration of DMSO was 
maintained at 0.1% DMSO. Afterward, the supernatant of each well was removed, washed once with 
PBS medium and replaced by 100 µL (0.5 mg/mL) of MTT in L15 medium. The 96-well plate was 
incubated for another 2 hours before the MTT solution was discarded and then 100 µL/well of DMSO 
was added to dissolve the resulted formazan product. The absorbance was measured at 570 nm, 
with reference at 630 nm in a Spectra MAX 190 multi-well plate reader. The relative cell viability 
percentage was calculated by comparing absorbance of treated cells with a control, where 0.1% 
DMSO in L15 medium was applied instead of tamoxifen solution. 
 FTIR measurement of samples 
A continuous scan FTIR spectrometer (Frontier, Perkin Elmer Ltd., UK), fitted with a room 
temperature deuterated triglycin sulfate (DTGS) detector, was used to acquire FTIR spectra. After 
seeding the cells in the ATR trough for 24 hours, the cells on the ATR element were exposed to the 
IC50 (or 50% of the IC50) value of tamoxifen, toremifene, imatinib and doxorubicin by adding 
appropriate amounts of 50 mM stock solution (in L15 medium, 0.1% DMSO). The cells exposed to 
drugs were measured with a scanning time of 11 minutes. A spectrum was measured every 20 
minutes, and all measurements were acquired with a spectral resolution of 8 cm-1 and a spectral 
range of 1800 to 900 cm-1. The strong Norton-Beer apodization function and self-phase correction 
were chosen for the interferogram process. Spectrum 10 software (Perkin Elmer Ltd., UK) was used 
for all data pre-treatment processing. Spectra of cells were continuously monitored from the 
moment after seeding the cells on the ATR element for 24 hours. For control, 0.1% DMSO was added 
to the medium and measured for another 24 hours. A spectrum of L15 medium was used as a 
background to obtain the full spectra of cells with the water vapour subtracted. For difference 
spectra, the first spectrum of cells immediately after the addition of drugs was used as a background 
to highlight the changes in live cells because of introducing the compound.  All measurements were 
made in triplicate.   
Principal Component Analysis (PCA) 
PCA was carried out using PyChem Software (http://pychem.sourceforge.net/).52 This analysis was 
applied to reduce the dimension of the spectroscopic data. Correlation matrix and Nonlinear 
Iterative Partial Least Squares (NIPALS) were selected for the PCA analysis. Before analysis, spectra 
were truncated to 2000-900 cm-1 wavenumber and then an interactive baseline correction using the 
Spectrum 10 software (Perkin Elmer) was performed based on the minima absorbance at 2000, 
1800, 1757, 1480, 1000 and 950 cm-1 wavenumbers. Vector normalisation was calculated in 
Microsoft ®Excel 10, in which spectra were divided by the square root of the sum of the mean 
intensities squared. PC1, PC2 and PC3 were selected to represent the spectral variances, as they 
account for more than 85% of the variances (see supplementary Figure 2S) and plotted at different 
time points. 
Results and Discussion  
A representative ATR-FTIR spectra of live MDA-MB-231 cells in the first 24 hours after seeding at 
~2.0 X 105 cell/cm-2 acquired by multi-reflection ATR-FTIR spectroscopy in the region 1800-900 cm-1 
is shown in Figure 2. Cells were seeded at a high density to obtain a high coverage of the ATR 
measuring surface to maximise the signal from the cell. The analysis is focused in the 1800-900 cm-1 
region because this is the region that contains the most information about the chemical composition 
of the cell where water does not have strong absorbance, except the amide I region, which is 
excluded in the PCA analysis. Although measurements were made every 20 min, with a scanning 
time of 11 min, a shorter measurement time and higher measurement rate can be achieved using a 
MCT detector but it was found to be not necessary in this work because the changes in the cell were 
found to be relatively slow.15 The first hour after seeding cells on the ATR element has shown a 
relatively weak absorbance of ~0.04 absorbance units for the amide II band at ~1545 cm-1 (Figure 2). 
The amide II band absorbance has rapidly increased in the next 8 hours, followed by a slow but 
steady increase from the 12 to 24 hours, which indicates the attachment of MDA-MB-231 cells on 
the ZnS ATR crystal is completed within the first 12 hours, followed by cell growth. Cells were left for 
24 hours to allow enough time for intimate adherence on the ATR crystal, which reproducibly 
reaching the plateau absorbance of ~0.2. The changes in amide II absorbance after 24 hours of 
seeding is relatively small, and therefore the chance of detecting subtle cellular changes induced by 
anticancer drugs will be increased, particularly with a high SNR gained by using the current FTIR 
method.  
 Figure 2: A typical set of ATR-FTIR spectra of live MDA-MB-231 cells for 24 hrs after seeding 
(Control). A straight line between 1800-950 cm-1 was used to baseline the spectra.   
In this study, four drugs (tamoxifen, toremifene, imatinib and doxorubicin) were tested at their IC50s 
(the concentration of drug required to inhibit the growth of cells by 50%) determined by standard 
MTT assay51 instead of using the same concentration for each drug. The IC50 is a commonly used 
concentration to normalise and study the effects of anticancer compounds. This will help in 
normalising the differences between drug performance due to the difference in the rate of drug 
uptake and transport. Previous studies have shown that these drugs exhibit their cytotoxic effect 
against MDA-MB-231 cells through targeting different cellular pathways that are essential for 
survival and proliferation of cells. For example, imatinib has been shown to have anti-proliferative, 
cytostatic and apoptotic effect due to its ability to block the platelet derived growth factor receptor 
(PDGF-Rβ).53-57 Additionally, tamoxifen has been shown to induce apoptosis mediated by an 
oestrogen-independent pathway in triple negative breast cancer cell lines (MDA-MB-231, MDA-MB-
468, MDA-MB-453 and SK-BR-3).58, 59 Doxorubicin is a DNA alkylator which is used in the treatment 
of triple negative breast cancer and its activity against MDA MB 231 is well documented.60, 61 Figure 
3A shows an example of the MTT assay result for the MDA-MB-231 cells treated with (1-100 µM) of 
tamoxifen for 24 hours is shown and the IC50 was found to be at ~25 µM (refer to Table 1). When 
exposing the attached live MDA-MB-231 cells on the ATR element to this concentration, where a 
50% decrease in cell is expected, Figure 3B shows an approximately 37% decrease in amide II 
absorbance relative to the control. The difference could be a result of the relatively high confluence 
of cells used in the live cell ATR test, as compared to the MTT assay, and the fact that the amide II 
absorbance in the live cell FTIR measurement reflects on cell detachment upon cell death, while the 
MTT assay is based on the reduction in mitochondria activities. Nevertheless, the cytotoxic effect of 
the drug is clearly shown by both measurement methods.  
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Figure 3: A) Cell Viability Percentage of MDA-MB-231 treated with tamoxifen for 24 hrs. B) Amide 
II (~1546 cm-1) normalised absorbance (percentage) of live MDA-MB-231 cells as a function of time 
following the addition of 0.1% drug vehicle (DMSO; Black) and 25 µM Tamoxifen (Blue) for 24 hrs. 
Peaks normalised at absorbance  value when 0.1% DMSO and 25 µM Tamoxifen added to cells 
(time 0 = 100 %) 
It is important to emphasise that the FTIR measurements were repeated three times by seeding cells 
from separate tissue culture flasks for each condition. The small standard deviation (shown by the 
error bars) in Figure 3B clearly shows the high reproducibility of the current FTIR method in 
measuring the response of live cells after exposure to the drug vehicle and IC50 concentration of 
anticancer drugs. Difference spectra (using the first spectrum measured immediately after adding 
drugs as a background) was used to show the subtle spectral changes of cells after the exposure to 
anticancer drugs. To maintain the clarity of presentation, vector normalised spectra collected at the 
2nd, 4th and 6th hours of treatment have been selectively presented, which reflect the changes in the 
cellular components as a function of time after drug exposure and are shown in Figure 4. 
Table 1: Summary of Drugs’ Mode of Action 
Drug Mode of Action IC50 (µM) 
  
Tamoxifen 
1. Selective Oestrogen Receptor Modulator (SERMs) also known 
as Oestrogen-Dependent Pathway mainly in ER-positive breast 
cancer (e.g. MCF7) 
2. Oestrogen-Independent Pathway in triple negative breast 
cancer cell (e.g. MDA-MB-231) 
 
 
~25.0 
 
Toremifene 
1. Selective Oestrogen Receptor Modulator (SERMs) also known 
as Oestrogen-Dependent Pathway mainly in ER-positive breast 
cancer (e.g. MCF7) 
2. Oestrogen-Independent Pathway in triple negative breast 
cancer cell (e.g. MDA-MB-231) 
 
~30.0 
Imatinib   Tyrosine Kinase Inhibitor (TKI) ~50.0 
Doxorubicin  DNA-Intercalating Agent ~ 3.0 
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From the visual inspection of the spectra, it is evidence that the anticancer drugs of different modes 
of action induced significant spectral changes at different time points that are different from each 
other and from control, while drugs with the same mode of action show similar changes. For 
instance, the difference spectra of control cells in Figure 4 at different time points resemble the 
typical spectrum of cell as shown in Figure 2. In comparison to the control cells, cells exposed to 
doxorubicin have shown a decrease in the absorbance in the 1085 cm-1 and 1050 cm-1 regions with a 
clearer drop after 4 and 6 hours of exposure while amide II bands ~ 1545 cm-1 was relatively similar 
(Figure 4B and 4C). These changes were previously observed with PC3 cells treated with 1.0 µM 
doxorubicin and might be associated with DNA phosphates backbone changes because of the DNA 
disintegrating effect of doxorubicin (a well-known intercalating agent).16 The exposure of cells to 
imatinib highlighted a significant increase in the absorbance peaks at 1600 cm-1 and 1400 cm-1, 
which coincide with the symmetrical and asymmetrical stretching modes of carboxylate peaks, 
suggesting an increase in carboxylate metabolites in the cells as shown in Figure 4 A-C.  The cells 
treated with tamoxifen and toremifene have also shown an increase in the 1600 cm-1 and 1400 cm-1 
peaks but at a lower level, comparing to imatinib, in the 2 hours and 4 hours treatment. However, 
the spectral change for tamoxifen, toremifene and imatinib become similar in the 1600-1400 cm-1 
region after 6 hours of exposure. Although these spectral changes were similar in the 1600-1400 cm-
1 region, it can be observed that imatinib induced these changes faster than tamoxifen and 
toremifene (Figure 4A). It is important to emphasise that a remarkable similarity between tamoxifen 
and toremifene in the 1600-950 cm-1 region in all hours of treatments were clearly shown in Figure 4 
demonstrating that anticancer drugs with same mode of actions are likely to cause similar cellular 
changes. The peaks observed (i.e. 1600 cm-1 and 1400 cm-1) were not detected in the ATR-FTIR 
spectra of imatinib, tamoxifen and toremifene (see supplementary Figure 6S), which mainly 
associated with the cellular spectral changes in response to drugs.  
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Figure 4: FTIR vector normalised difference spectra of live MDA-MB-231 cells after exposure to 
0.1% DMSO (drug vehicle; control(C)) and IC50 of tamoxifen (TM), toremifene (TR), imatinib (IM) 
and doxorubicin (DX) for 2, 4 and 6 hours (A, B, C, respectively). The spectra presented are average 
of three repeated measurements (see supplementary Figure 3S the spectra with error bars).  
PCA was also used for the analysis of the subtle cellular changes of cells exposed to tamoxifen, 
toremifene, imatinib and doxorubicin at IC50.  The mode of actions of drugs used in this study are 
summarised in Table 1. The PCA of cellular response of control and cells exposed to IC50 of 
tamoxifen, toremifene, imatinib and doxorubicin in the 2nd hour, 4th hour and the 6th hour were 
shown in Figure 5 A-C, respectively. Further analysis using 2nd derivative vector normalised 
difference spectra of the same data is shown in (supplementary Figure 4S and 5S). First, it can be 
observed that the repeated experiments of untreated control cells are tightly clustered together in 
the score plot, demonstrating the reproducibility of this method (Figure 5 A-C, blue circle). In Figure 
5A, PC1 (68.28% of variances) of the 2nd hour exposure to drugs highlighted changes in the 1600 and 
1400 cm-1 absorbance peaks which confirms the observation made in (Figure 4A). In addition, this 
PC, which gives a clear separation of cells treated with tamoxifen, toremifene and imatinib from 
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control and doxorubicin, highlights changes in the 1240-950 cm-1 where absorbance peaks of 
asymmetric PO2− of nucleic acids, lipids and phosphorylated proteins (~1237 cm-1 ), C−O of protein 
side chain groups and carbohydrate (~1150 cm-1), symmetric PO2− of nucleic acids and PO4−2 
phosphorylated proteins, C−O−C and C−O−P of polysaccharides (~1080 cm-1), C−O of carbohydrates 
(~1050-1036 cm-1) and PO4-2 of phosphorylated proteins and nucleic acids (~990-970 cm-1). PC2 
represents 15.15% of variances and mainly separates tamoxifen and toremifene from control, 
imatinib and doxorubicin and shows absorbance peaks at 1510 cm-1, 1243 cm-1, 1174 cm-1, and 1022 
cm-1. To consider the origin of these peaks, ATR-FTIR spectra of 10 mM of drugs in 10% DMSO (see 
supplementary Figure 6S) were collected to compare with this PC loading, which has shown that the 
peaks at 1510 cm-1, 1243 cm-1 and 1174 cm-1 are originated from tamoxifen and toremifene 
accumulation in cells in the first 2 hours of treatment. In addition to these peaks, PC2 also 
highlighted changes in the 1150-950 cm-1 associated with changes in carbohydrates and 
phosphorylated cellular compounds as previously described and none of these peaks are originated 
from drug spectra (see supplementary Figure 6S). PC3 (Figure 5B) accounts for 7.25% of the 
variances provides little separation between the different treatment. The PCA of the 4th hour 
exposure to drugs is shown in (Figure 5C and 5D). PC1 (74.81 % of variances) highlighted changes in 
the 1600 and 1400 cm-1 absorbance peaks and changes in the 1150-950 cm-1. In a similar pattern, it 
separated cells treated with tamoxifen, toremifene and imatinib from control and doxorubicin. 
However, the separation between tamoxifen or toremifene and imatinib has reduced compared to 
the PC1 of the 2nd hour data. In addition, PC2 of the 4th hour (represents 12.19% of variances) 
separated doxorubicin treated cells from control cells as shown in (Figure 5C, red square) and 
highlighted the spectral changes in the carbohydrates and phosphates region at 1150-970cm-1. Most 
importantly, absorbance peaks of tamoxifen and toremifene become less significant in this PC2 and 
contributed minimally to the separation between tamoxifen, toremifene and imatinib. Comparing to 
the spectrum of doxorubicin shown in Figure 6S to the loading plot of PC2, no similarity can be 
observed highlighting that the separation of control from doxorubicin treated cells are mainly based 
on the changes in the cellular composition rather than drug accumulation.  PC3 (Figure 5D) accounts 
for 5.16% of the variances mainly separates doxorubicin from control. Figure 5E and 5F show the 
PCA of the 6th hour exposure in which PC1 accounts for 72.60% of variances and separates cells 
treated with tamoxifen, toremifene and imatinib from control and doxorubicin treated cell, similar 
to that of the PC1 from the 4th hour data (Figure 5C). However, there was no clear separation 
between tamoxifen or toremifene and imatinib in PC1 from the 6th hour data. PC2 (14.55%) and PC3 
(5.98%) separate doxorubicin treated cells from control and clearly demonstrates the changes in the 
1240-970 cm-1 associated with changes in the phosphorylated proteins, nucleic acids and 
carbohydrates. Comparing to the drug spectra in Figure 6S, the PCA has shown that spectral changes 
are not due to the accumulation of drug in both the 4th and 6th hour data.  In all cellular changes 
described here, PC loadings show several changes in the region of 1240-970 cm-1 which mainly 
associated with carbohydrates and phosphorylation/dephosphorylation of proteins and nucleic 
acids. Imatinib is a tyrosine kinase inhibitor (TKIs) and exert its action by inhibiting the 
phosphorylation process of proteins. These changes have been previously shown in PC12 cells during 
neuronal differentiation induced by NGF and were mainly assigned with protein phosphorylation.62 
Tamoxifen and toremifene are selective oestrogen receptor modulators (SERMs) and characterised 
by their competition with oestrogen for binding to the oestrogen receptor (ER) and ultimately 
inhibiting the proliferation of ER-positive breast cancer tissue or so-called ER-dependent pathway. 
Additionally, tamoxifen has been shown to have an ER-independent effects in triple negative breast 
cancer cells (e.g. MDA-MB-231) associated with inhibition of cancerous inhibitor of protein 
phosphatase 2A (CIP2A) and phospho-Akt (p-Akt).59 The similarity between the effect of imatinib, 
tamoxifen and toremifene from the 6th hour onward could be attributed to their influence on the 
phosphorylation/dephosphorylation status of proteins, carbohydrates and nucleic acids. However, at 
this stage, it is not possible to confirm the specific biomolecules that caused these changes due to 
the overlapping of cellular component peaks in this region. It is important to emphasise that 
doxorubicin also showed cellular changes in the phosphates and carbohydrates region mainly in the 
1150-970 cm-1, but the PC loadings in the 2nd, 4th and 6th hr clearly showed no overlapping in 
separation between doxorubicin treated cells and tamoxifen, toremifene and imatinib cells. This 
suggests that doxorubicin has a different mode of action on the MDA-MB-231 cells in comparison to 
tamoxifen, toremifene and imatinib. Although the early hours (i.e. 2nd hr) showed some overlap 
between doxorubicin and control (see Figure 5A), the separation becomes very clear in the longer 
exposure time (see Figure 5C-F) and indicates the time-dependent effect on the cells.  
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Figure 5: PCA scores and their corresponding loadings of FTIR vector normalised difference spectra 
of live MDA-MB-231 cells after exposure to 0.1% DMSO (Control) and IC50 of tamoxifen (TM), 
toremifene (TR), imatinib (IM) and doxorubicin (DX) in the 2nd hr (A and B), 4th hr (C and D) and 6th 
hr (E and F). 
We further investigated the sensitivity of live cell ATR FTIR method in the detection of cellular 
responses at lower concentrations (e.g. 50% of IC50 value). Previous study on non-cytotoxic dose 
using Raman imaging has shown that it is clinically important to measure the effect of drug to cells at 
low concentrations.63  To our knowledge, it is the first time that the ATR method was used to 
examine live cells response to sub-IC50 concentrations. PCA was applied to detect spectral changes 
in cells in response to the 50% of IC50 concentration of tamoxifen, toremifene, doxorubicin and 
imatinib (~12.5, 15, 1.0 and 25 µM, respectively). With the lower drug concentration, the results 
have shown that the separation between drug treated cells happens at longer incubation time. The 
PC1 (78.23% of variances, Figure 6A) of the 6th hour of exposure to 50% IC50 has separated the 
response of cells exposed to imatinib from control, tamoxifen, toremifene and doxorubicin. 
However, cells treated with tamoxifen, toremifene and doxorubicin were not separated. This may be 
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due to the dose-dependent response of cells to these drugs or the resistant mechanism against 
these drugs employed by the cells at lower concentration, as cells show only limited response to 
anticancer drugs in the early hours. On the other hand, PC2 (13.95% variances, Figure 6A) separated 
the control cells from the drug treated cells and shows that the differences are mainly in the 
carbohydrates and phosphate band regions. In the PC3 (4.12% variances, Figure 6B), two peaks of 
tamoxifen and toremifene at 1243 cm-1 and 1174 cm-1were detected (see supplementary Figure 6B) 
due to the accumulation of drugs in the cells. Despite these peaks, PC3 also show changes in the 
region 1150-970 cm-1 associated with carbohydrates and phosphates that is not originated from the 
drugs themselves. Further investigation of a longer exposure of cells in drug (i.e. at 24 hours) is 
shown in (Figure 6C and 6D). In contrast to the early response, PC1 (60.01 % of variances) and PC2 
scores (27.3% of variances) and its corresponding loading plots gives a clear separation to all drugs 
and the PC loadings did not show any contribution from the drugs spectra. This demonstrated that 
the separation in the PCA is based on the cellular response rather than drug accumulation.   
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 Figure 6: PCA scores and their corresponding loadings of FTIR vector normalised difference spectra 
of live MDA-MB-231 cells after exposure to 0.1% DMSO (Control) and 50% IC50 of tamoxifen (TM), 
toremifene (TR), imatinib (IM) and doxorubicin (DX) in the 6th hr (A and B) and 24th hr (C and D). 
To obtain an overall view of the spectral changes that give the best separation between drugs and 
control, pairwise PCA analysis of control versus each of the drugs in the 24th hour of cells treated 
with 50% IC50 were performed as it has been shown to provide the best separation (Figure 6C). In all 
pairwise PCA analysis, PC1 provides a clear separation between the control and the treated cells 
(Figure 7A-C) and accounts for more than 78% of the variances. The PC1 loadings (Figure 7D) 
demonstrate that most spectral changes are observed in the 1240-970 cm-1 region, which is sensitive 
to the changes in the phosphate moiety particularly for tamoxifen, toremifene and imatinib.64 While 
these spectral changes occur in the same IR region, it is clearly shown that the cellular components 
that lead to such pattern of absorbance are remarkably different. In fact, this is expected as these 
drugs are known to target different cellular pathways as previously described. For instance, 
tamoxifen has been shown to induce apoptosis because of its phosphatases activity that lead to the 
downregulation of p-Akt pathway. This can produce a change to the absorbance in the sym(PO2)- and 
asym(PO2)-  vibrational mode due to the inhibition of protein phosphorylation. In addition, PC1 
loadings of control versus doxorubicin in Figure 7D (Red line) shows a clear spectral change in three 
IR absorbance bands at 1225, 1085, 970 cm-1 that are associated with DNA phosphates backbone. 
Imatinib inhibits the tyrosine kinases activity and expected to cause different changes in the 
phosphates absorbance due to the reduction in the phosphorylation of the tyrosine side chain 
(Figure 7D, Blue line).”  
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Figure 7: (A) shows the pairwise PC1 scores of control (1-3) versus tamoxifen (4-6) and toremifene 
(7-9). (B) shows control (1-3) versus imatinib (4-6) and (C) shows control (1-3) versus doxorubicin 
(4-6). (D) represents the corresponding PC1 loadings of tamoxifen and toremifene (black), imatinib 
(blue) and doxorubicin (red). All samples were run in triplicates. 
Conclusions 
The combined live-cell FTIR spectroscopy with principal component analysis has shown to be able to 
distinguish the different responses from the testing cell (MDA-MB-231) treated with four different 
drugs of known modes of action. Drugs that have the same mode of action (tamoxifen and 
toremifene) were grouped together, while drugs with different modes of action (imatinib and 
doxorubicin) were differentiated in the analysis. Using PCA, clear separation between drugs with 
different modes of action was found, with a short drug treatment time of less than 6 hours at IC50 
concentration. When cells were treated with lower drug concentrations (i.e. 50% of IC50), clear 
separation was found at a later treatment stage of 24 hours. The results demonstrated the potential 
of using this complementary tool for pre-clinical drug screening studies, which could improve the 
efficiency of drug screening programs by confirming the modes of action of drugs without recourse 
to expensive and laborious biochemical assays. The time course study has revealed that the best 
separations are obtained at between 2-6 hours of drug treatment at IC50, with the best separation 
of drug found at different time points depending on mode of action of the drug. The pairwise PCA 
analysis has further reinforce the relationship between spectral changes to the known mode of 
PCA Scores
t[
1
] 
(
8
0
.8
2
%
)
C
TM
TR
1 2 3 4 5 6 7 8 9
-0.30
-0.25
-0.20
-0.15
-0.10
-0.05
-0.00
0.05
0.10
0.15
0.20
0.25
C
C C
TM
TM
TM
TR
TR TR
PCA Scores
t[
1
] 
(
7
1
.1
9
%
)
C
IM
1 2 3 4 5 6 7
-0.30
-0.25
-0.20
-0.15
-0.10
-0.05
-0.00
0.05
0.10
0.15
0.20
0.25
C
C C
IM IM IM
PCA Scores
t[
1
] 
(
8
8
.4
1
%
)
C
DX
1 2 3 4 5 6 7
-0.30
-0.25
-0.20
-0.15
-0.10
-0.05
-0.00
0.05
0.10
0.15
0.20
0.25
C
C C
DX
DX
DX
-0.15
-0.1
-0.05
0
0.05
0.1
0.15
9501000105011001150120012501300135014001450150015501600
TM & TR DX IM
D
1212
1072
1033 976
1242
1193
1089
1120
1040
965
1225
970
1085
Wavenumber cm-1 
Lo
ad
in
gs
 
P
C
1
 S
co
re
s 
(8
1
.6
2%
) 
A B C 
Sample Number Sample Number Sample Number 
P
C
1
 S
co
re
s 
(9
2
.8
1%
) 
P
C
1
 S
co
re
s 
(7
8
.8
0%
) 
action of drugs. This highlights the advantages of the demonstrated technique where many time 
points can be measured in a single measurement. The next step is to combine the live cell FTIR 
method with high-throughput technique such as FTIR imaging to study multiple drug samples in 
individual wells in parallel.65   
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